Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 6/20 | 0.82 |
| ▸ | AR | P10275 | 5/20 | 0.82 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.82 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.82 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.82 |
| ▸ | NR3C1 | P04150 | 13/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.80 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.80 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.80 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.68 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.63 |
| ▸ | RAB9A | P51151 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | USP2 | O75604 | 2/20 | 0.60 |
| ▸ | MLNR | O43193 | 1/20 | 0.60 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3676225 | 1.00 | PGR (0.82) | PGRARADORA3CHRM1ADRA1A | |
| SCHEMBL192155 | 1.00 | PGR (0.82) | PGRARADORA3CHRM1ADRA1A | |
| SCHEMBL1695741 | 1.00 | PGR (0.82) | PGRARADORA3CHRM1ADRA1A | |
| SCHEMBL17748176 | 1.00 | PGR (0.82) | PGRARADORA3CHRM1ADRA1A | |
| SCHEMBL2554938 | 1.00 | PGR (0.82) | PGRARADORA3CHRM1ADRA1A | |
| SCHEMBL6842246 | 1.00 | PGR (0.82) | PGRARADORA3CHRM1ADRA1A | |
| SCHEMBL4219206 | 1.00 | PGR (0.82) | PGRARADORA3CHRM1ADRA1A | |
| SCHEMBL5535751 | 1.00 | PGR (0.82) | PGRARADORA3CHRM1ADRA1A | |
| SCHEMBL7901488 | 1.00 | PGR (0.82) | PGRARADORA3CHRM1ADRA1A | |
| SCHEMBL1859037 | 1.00 | PGR (0.82) | PGRARADORA3CHRM1ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3741772-B1 | PREPARATIONS OF HYDROPHOBIC THERAPEUTIC AGENTS, METHODS OF MANUFACTURE AND USE THEREOF | NICOX OPHTHALMICS INC (US) | 2024-06-19 | — | — | EP | disclosed |
| US-10954263-B2 | Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof | Nicox Ophthalmics, Inc (US) | 2021-03-23 | — | — | US | disclosed |
| EP-3741772-A1 | PREPARATIONS OF HYDROPHOBIC THERAPEUTIC AGENTS, METHODS OF MANUFACTURE AND USE THEREOF | Nicox Ophthalmics, Inc. (US) | 2020-11-25 | — | — | EP | disclosed |
| EP-3517541-B1 | POLYMORPHIC FORM OF FLUTICASONE PROPIONATE | NICOX OPHTHALMICS INC (US) | 2020-07-15 | — | — | EP | disclosed |
| EP-3517541-A1 | POLYMORPHIC FORM OF FLUTICASONE PROPIONATE | Nicox Ophthalmics, Inc. (US) | 2019-07-31 | — | — | EP | disclosed |
| US-20190169224-A1 | PREPARATIONS OF HYDROPHOBIC THERAPEUTIC AGENTS, METHODS OF MANUFACTURE AND USE THEREOF | Nicox Ophthalmics, Inc | 2019-06-06 | — | — | US | disclosed |
| EP-2847207-B1 | Fluticasone propionate nanocrystals | NICOX OPHTHALMICS INC (US) | 2019-03-27 | — | — | EP | disclosed |
| US-10174071-B2 | Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof | NICOX OPHTHALMICS, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180022775-A1 | PREPARATIONS OF HYDROPHOBIC THERAPEUTIC AGENTS, METHODS OF MANUFACTURE AND USE THEREOF | ACIEX THERAPEUTICS, INC. | 2018-01-25 | — | — | US | disclosed |
| US-9822142-B2 | Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof | NICOX OPHTHALMICS, INC. (US) | 2017-11-21 | — | — | US | disclosed |
| US-20100069342-A1 | FORMOTEROL/STEROID BRONCHODILATING COMPOSITIONS AND METHODS OF USE THEREOF | DEY, L.P. (US) | 2010-03-18 | — | — | US | disclosed |
| US-20090306228-A1 | ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS | SHIRE LLC (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090253792-A1 | ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS | SHIRE LLC (US) | 2009-10-08 | — | — | US | disclosed |
| US-7427600-B2 | Active agent delivery systems and methods for protecting and administering active agents | SHIRE LLC (US) | 2008-09-23 | — | — | US | disclosed |
| US-20070232529-A1 | mesalamine covalently attached to carrier peptide at C-terminus, interspersed and/or side chain; releasing into bloodstream; reducing dosage | NEW RIVER PHARMACEUTICALS INC. (US) | 2007-10-04 | — | — | US | disclosed |
| US-20040037783-A1 | Pharmaceutical formulation of fluticasone propionate | SMITHKLINE BEECHAM CORPORATION (US) | 2004-02-26 | — | — | US | disclosed |
| US-6630129-B2 | Completely dissolved in hydrofluoroalkane propellant; aerosol; 1,1,1,2-tetrafluoroethane; ethanol as solubilizing agent; administration by inhalation | SMITHKLINE BEECHAM CORPORATION | 2003-10-07 | — | — | US | disclosed |
| US-20030138559-A1 | Process for manufacturing a metered dose inhaler | SMITHKLINE BEECHAM CORPORATION | 2003-07-24 | — | — | US | disclosed |
| US-20030086876-A1 | Pharmaceutical formulation of fluticasone propionate | GLAXO GROUP LIMITED (GB) | 2003-05-08 | — | — | US | disclosed |
| US-20020183293-A1 | Administering durg comprising formoterol, or a derivative thereof and asteroidal anti-inflammatory agent, or a derivative in a pharmacologically suitable fluid, wherein the drug formulation is stable during long term storage | MYLAN PHARMACEUTICALS, INC. | 2002-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253792-A1 | ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS | HDGF, CTSA, IAPP | PGR 1899/4885AR 3288/4885ADORA3 1906/4885 |
| US-20090306228-A1 | ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS | HDGF, CTSA, IAPP | PGR 1899/4885AR 3288/4885ADORA3 1906/4885 |
| US-20070232529-A1 | mesalamine covalently attached to carrier peptide at C-terminus, interspersed and/or side chain; releasing into bloodstream; reducing dosage | VIP, BST2, FCGR3B | PGR 2787/4885AR 4423/4885ADORA3 619/4885 |
| US-20020183293-A1 | Administering durg comprising formoterol, or a derivative thereof and asteroidal anti-inflammatory agent, or a derivative in a pharmacologically suitable fluid, wherein the drug formulation is stable during long term storage | AREG, IL5, IL17A | PGR 2483/4885AR 276/4885ADORA3 131/4885 |
| US-20100069342-A1 | FORMOTEROL/STEROID BRONCHODILATING COMPOSITIONS AND METHODS OF USE THEREOF | ADRB2, CYP11B2, ADRB3 | PGR 2160/4885AR 487/4885ADORA3 390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.